PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making

Area of Science:

• Nuclear Medicine
• Radiology
• Oncology

Background:

• Prostate-Specific Membrane Antigen - Radiotracer Imaging Reporting and Data System (PSMA-RADS) version 1 (2017) established a framework for classifying PSMA-targeted PET scans.
• The initial version focused on findings outside the prostate using a five-point scale.
• Limitations in the original PSMA-RADS necessitated an update to improve its clinical utility.

Purpose of the Study:

• To explore the modifications introduced in the updated PSMA-RADS version.
• To evaluate the impact of the revised PSMA-RADS on clinical management of prostate cancer.
• To inform radiologists about advancements in PSMA-targeted imaging for better patient care.

Main Methods:

• Review and analysis of the updated PSMA-RADS version (2022).
• Comparison of the updated framework with the initial PSMA-RADS version (2017).
• Exploration of lesion-level and patient-level classifications, including confidence and probability scores.

Main Results:

• The updated PSMA-RADS version refines category definitions and addresses limitations of the initial scale.
• The revised framework incorporates both lesion-level and patient-level classifications.
• Enhanced confidence and probability scores are provided to support clinical decision-making.

Conclusions:

• The updated PSMA-RADS version offers improved classification for PSMA-targeted PET scans.
• The revised scale is expected to enhance the guidance of clinical decisions in prostate cancer management.
• This advancement supports multidisciplinary collaboration and optimizes patient care through more accurate imaging interpretation.